Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Liver-Directed Therapy or PRRT for Well-Differentiated Neuroendocrine Tumors
NCT03457948Phase 2Completed
- Start
- Aug 2018
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in Neuroendocrine Neoplasm (NEN) (3 arms). Primary endpoints: Overall Response Rate at 25 months and Treatment-related Adverse Events at 26 months. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03457948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457948.